| abstract |
This case discloses an antigen binding protein specific for the HLA-A2 restricted Ras peptide. The antigen binding protein encompasses antibodies in a variety of formats, including full length antibodies, substantially intact antibodies, Fab fragments, F(ab')2 fragments, and single chain Fv fragments. The disclosures herein also contemplate fusion proteins (such as scFv fused to immunoglobulin or T cell receptor domains) and bispecific antibodies that incorporate specificity for the antigen binding regions of each peptide. In addition, the disclosure herein also encompasses immunoconjugates which may comprise antibodies and radioisotopes, fluorescent or other detectable labels, cytotoxins, or other molecules attached thereto. In addition to other things, immunoconjugates can be used to deliver a drug to induce therapeutic efficacy or to promote immune effector function. |